跳至主要内容
临床试验/NCT00150410
NCT00150410已完成3 期

A One-Year, Open, Randomized, Parallel, Three-Arm Study Comparing Exubera® (Insulin Dry Powder Pulmonary Inhaler) vs. Avandia® (Rosiglitazone Maleate) as Add-On Therapy vs. Exubera® Substitution of Sulfonylurea in Patients With Type 2 Diabetes, Poorly Controlled on Combination Sulfonylurea and Metformin Treatment

Pfizer120 个研究点 分布在 2 个国家目标入组 626 人开始时间: 2003年1月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Pfizer
入组人数
626
试验地点
120
主要终点
Glycosylated hemoglobin

研究概览

简要总结

  • Whether a combination of three therapies - metformin and a sulfonylurea plus Exubera, an investigational drug, controls your diabetes at least as much as a triple combination therapy of metformin and a sulfonylurea plus Avandia, a Food and Drug Administration (FDA) approved drug.
  • Whether a combination of two therapies - metformin plus Exubera controls your diabetes at least as much as a as a triple combination therapy of metformin and a sulfonylurea plus Avandia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 2 diabetes
  • Currently treated and on a stable doses of drugs for the preceding two (2) months

排除标准

  • Type 1 Diabetes

结局指标

主要结局

Glycosylated hemoglobin

次要结局

  • insufficient clinical response.
  • Change from baseline in fasting plasma glucose. Other secondary efficacy
  • endpoints include, body weight, patient reported outcomes, incidence and severity
  • of hypoglycemic episodes, cough questionnaire, and discontinuation rate due to

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (120)

Loading locations...

相似试验

Demonstrate Exubera Works As Well As Avandia When... | 临床试验